The advent of novel therapies targeting immune checkpoint regulators, such as nivolumab, has revolutionized therapeutic modalities against melanomas.1 Adverse effects could be caused by characteristic immune-related mechanisms. We report the first case, to our knowledge, of severe oral ulcers without severe pyrexia or diarrhea associated with nivolumab treatment and discuss the potential mechanism presenting as graft-vs-host disease (GVH)-like reactions.
Namiki T, Hanafusa T, Ueno M, Miura K, Yokozeki H. Severe Oral Ulcers Associated With Nivolumab Treatment. JAMA Dermatol. 2017;153(2):235–237. doi:10.1001/jamadermatol.2016.4443
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: